ReviewAutoimmunity reviews2010
PD-1, gender, and autoimmunity.
Review in Autoimmunity reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials.Frontiers in pharmacology · 2022Pooled it
- Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies.PloS one · 2016Pooled it
- Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology.European urology · 2012Pooled it
- Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study.Journal for immunotherapy of cancer · 2026Article
- Gender Matters. Sex-related Differences in Immunotherapy Outcome in Patients with Non-small Cell Lung Cancer.Current cancer drug targets · 2025Article
- Androgen aggravates aortic aneurysms via suppression of PD-1 in mice.The Journal of clinical investigation · 2024Article
- Association of tuberculosis risk with genetic polymorphisms of the immune checkpoint genes PDCD1, CTLA-4, and TIM3.PloS one · 2024Article
- Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma.Journal of cancer research and clinical oncology · 2023Article
- The Relationship Between PD-1(rs2227981) and PD-L1(rs2890658) Polymorphisms and Urothelial Cell Carcinoma.Cureus · 2023Article
- Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.Cancers · 2023Article
- Estrogens, Cancer and Immunity.Cancers · 2022Review
- [Estradiol inhibits differentiation of mouse macrophage into a pro-inflammatory phenotype by upregulating the IRE1Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- Sex hormones and immune system: Menopausal hormone therapy in the context of COVID-19 pandemic.Frontiers in immunology · 2022Review
- Sex difference in the expression of PD-1 of non-small cell lung cancer.Frontiers in immunology · 2022Article
- Sex - a potential factor affecting immune checkpoint inhibitor therapy for cancers.Frontiers in immunology · 2022Article
- Association between forkhead box P3 expression level and gender of Iranian juvenile idiopathic arthritis patients.Reumatologia · 2022Article
- The Impact of Di-Isononyl Phthalate Exposure on Specialized Epithelial Cells in the Colon.Toxicological sciences : an official journal of the Society of Toxicology · 2021Article
- Review
- The effect of estrogen in coronavirus disease 2019.American journal of physiology. Lung cellular and molecular physiology · 2021Review
- The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer.Annals of translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Programmed death 1 (PD-1) and its ligands (PD-L1 and PD-L2) are responsible for inhibitory T cell signaling that helps mediate the mechanisms of tolerance and immune homeostasis. The PD-1:PD-L signaling pathway has been shown to play an important role in a variety of diseases, including autoimmune conditions, chronic infection, and cancer. Recently, investigators have explored the role of sex hormones in modulating the pathway in autoimmune conditions. Exploring the effects of sex hormones on the PD-1:PD-L pathway could shed light on the gender biased nature of many autoimmune conditions as well as aide in the development of therapeutics targeting the immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.